MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival.
MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.
The company could sell this MAT2203. Let's hope for the best. Perhaps MTNB can be bought by some larger pharmaceutical company. They are a good group of research scientists, biologists. Something boiling, going on. Wait and see.
Market Data 
Markets 
AI
